Pharmaceutical Companies

EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.

The contract includes multiyear options that could ultimately deliver up to USD 482 million if exercised, enabling Shionogi to establish a dedicated manufacturing facility in the United States.

BioNTech’s decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction

This setback follows Brinsupri’s unsuccessful phase 2 trial for chronic rhinosinusitis without nasal polyps, which also failed to meet its primary and secondary endpoints at both tested doses.

The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.

When combined with a reduced-calorie diet and regular physical activity, Foundayo helps patients shed excess weight and maintain their progress.

The drug works as a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, requiring no food or water restrictions before taking it.

Beyond the initial payment, Centessa shareholders are set to receive an extra USD9 per share in contingent value rights (CVR), which could increase the total deal value by USD1.5 billion.

Central to this deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.